<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04169828</url>
  </required_header>
  <id_info>
    <org_study_id>H18-03176</org_study_id>
    <nct_id>NCT04169828</nct_id>
  </id_info>
  <brief_title>The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis</brief_title>
  <acronym>OPT-JIA</acronym>
  <official_title>The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Arthritis Society, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IWK Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Eastern Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alberta Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McMaster Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal University Hospital Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial University of Newfoundland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Far too many kids and families live in dread over the weekly nausea and vomiting caused by
      methotrexate - a medicine that controls joint swelling in Juvenile Arthritis patients. If
      methotrexate is not tolerated, expensive alternative biological medications may be started.
      This registry-based pragmatic randomized controlled trial will evaluate if routine
      premedication with the anti-emetic drug Ondansetron, reduces nausea and vomiting and
      increases the proportion of children able to continue methotrexate. By preventing nausea
      before it starts, we hope to give kids and families a better quality of life and see a more
      cost-effective use of medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Purpose:

           To evaluate if routine pre-medication with the anti-emetic ondansetron reduces
           methotrexate intolerance and increases the proportion of children with JIA able to
           continue taking methotrexate, resulting in a better quality of life and more
           cost-effective medication use.

        2. Hypothesis:

           Prophylactic prescription of ondansetron with methotrexate will increase the proportion
           of children that remain on methotrexate and intolerance free one year after starting
           methotrexate, relative to prescription of ondansetron after intolerance symptoms
           develop.

        3. Justification:

           Methotrexate intolerance is thought to be largely the result of Pavlovian conditioning
           secondary to previous exposure and symptoms can be triggered by associated stimuli, such
           as a yellow liquid similar in color to methotrexate or the smell of alcohol cleansing
           swabs. This intolerance leads to poor adherence to optimal dosing or to stopping the
           medication altogether. Children who cannot adhere to optimal dosing or stop methotrexate
           may require expensive biologic medications to control their JIA. Methotrexate
           intolerance often leads to use of anti-emetic medications which, unfortunately, rarely
           reverse conditioned responses. In oncology anti-emetics are used prophylactically as
           premedication in all subjects receiving chemotherapy to prevent the establishment of
           conditioned intolerance.

           By conducting a registry-based pragmatic adaptive superiority randomized clinical trial
           we can include most subjects in whom the treatment may be used under the usual
           conditions of practice to demonstrate effectiveness under real word circumstances.
           Patients enrolled in a pragmatic trial are more representative because eligibility
           criteria are less strict. More so, a registry-based pragmatic RCT can also be much
           cheaper than a traditional RCT.

        4. Objectives:

      We will assign patients starting low-dose methotrexate for JIA 1:1 online using the CAPRI
      Registry and block randomization by centre, patient weight and JIA category to one of two
      groups:

      Intervention: Routine premedication with oral ondansetron (2, 4 or 8 mg for patient weights
      &lt;15Kg, 15-30Kg, &gt;30 Kg; 3 doses a week).

      Control: Oral ondansetron at the same dosing, prescribed only to those patients who develop
      methotrexate-induced nausea/vomiting during usual care.

      We will compare:

        1. The proportions of patients remaining on methotrexate with no intolerance between the
           two groups one year after starting methotrexate (primary objective).

        2. The cumulative incidence of:

             1. methotrexate intolerance

             2. attainment of inactive disease

             3. biologic medication initiation

        3. The mean quality of life scores and methotrexate intolerance severity scores between the
           two groups 4-8 months after starting methotrexate.

      We will also collect information on impacts on quality of life and medication utilization
      that will enable a future cost-effectiveness analysis.

      5) Research Design: Our trans-Canada team of clinicians, clinical epidemiologists, trialists
      and statisticians brings together all the necessary skills and expertise to successfully
      complete the proposed trial.

      We will conduct a CAPRI JIA Registry-based pragmatic adaptive superiority RCT as per the
      following methods.

      Registry-based: The trial will use infrastructure already in place for the CAPRI JIA
      Registry.

      Pragmatic: Broad inclusion criteria and simple outcome assessments compatible with usual
      care.

      Adaptive: This is a Planned Sample-Size Re-Estimation Adaptive Trial as described by Bhatt &amp;
      Metha [34].

      Superiority: Designed to test superiority (as opposed to non-inferiority) of ondansetron
      premedication.

      RCT: Treatments assigned by block randomization and analyses adjusted for post-randomization
      imbalances

      6) Statistical Analysis: Our primary outcome statistic is the ratio of two proportions
      (relative risk, RR), the proportion of children remaining on methotrexate with no intolerance
      in the intervention group divided by the same in the control group. This choice allows
      flexibility for the frequency of follow-up visits to be set-up as per clinical need,
      obviating the need for study-specific visits, increasing feasibility and decreasing costs. It
      is also not impacted by the times at which methotrexate intolerance or discontinuation occur
      which leads to simplicity in interpretation and analysis.

      Our sample size calculation is based on expressing the RR in the log scale and using
      established formulas for standard errors. With p&lt;0.05, power of 90% and expected methotrexate
      continuation with no intolerance of 50% in the control group and 75% in the intervention
      group the result is 79 evaluable subjects per group. We will aim to recruit 176 subjects
      total to allow for up to a 10% dropout rate, although we expect a dropout rate of &lt;5% based
      on our previous CAPRI studies.

      A preliminary analysis after recruitment of 90 subjects will consist of a two-sided
      confidence interval (CI) for the RR of continuing on methotrexate with no intolerance, where
      the confidence level is adjusted for information accrual as per Schoenfeld.

      The Data and Safety Committee will assess preliminary results according to the following
      guidance:

      If the CI is entirely below a relative risk of 1.2, the study will be stopped for futility.

      If the CI is entirely above a relative risk of 1.2, the study will be stopped and superiority
      will be claimed.

      If the CI includes a relative risk of 1.2, the trial will continue until the re-calculated
      full target sample is attained.

      The RR of 1.2 has been selected on clinical grounds. In a prospective study of 142 children
      with JIA starting methotrexate followed for one year, Van Dijkhuizen et al reported that 59
      patients developed intolerance and 11 discontinued methotrexate for other reasons, for a
      total of 72 (50.7%) remaining on methotrexate with no intolerance. An increase in this
      proportion to &lt;60% is deemed too small to justify the additional costs and risks of adding
      prophylactic ondansetron.

      The final analysis will be an intention to treat analysis conducted after the final sample
      size is achieved or at the time the study is stopped. All subjects enrolled in the study at
      that time will complete a one-year follow-up and will be included in the final analysis.
      Logistic regression models will be used to adjust effect estimates for post-randomization
      imbalances in the two groups (intervention, control). A secondary per-protocol analysis will
      be conducted on those subjects who received the assigned intervention for at least 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pragmatic RCTs use alternative designs to establish effectiveness of a treatment strategy in usual care. Pragmatic trials aim to include all subjects in whom the treatment may be used and are conducted under the usual conditions of practice to demonstrate effectiveness under real word circumstances. Patients enrolled in a pragmatic trial are more representative because eligibility criteria are less strict.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects that remain on methotrexate with no intolerance</measure>
    <time_frame>One year after starting methotrexate.</time_frame>
    <description>Intolerance will be defined as ≥6 points in the English or French versions of the validated Methotrexate Intolerance Severity Score, MISS [10, 36]. The MISS questionnaire takes less than 2 minutes to complete (see Appendix). It will be added to the Registry questionnaires completed by families online or on paper as per the CAPRI Centre usual Registry procedures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Methotrexate intolerance</measure>
    <time_frame>Within one year</time_frame>
    <description>The cumulative incidence of methotrexate intolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attainment of inactive disease</measure>
    <time_frame>Within one year</time_frame>
    <description>The cumulative incidence of attainment of inactive disease, defined by Wallace criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Starting a biologic medication</measure>
    <time_frame>Within one year</time_frame>
    <description>The cumulative incidence of starting a biologic medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of My Life scale</measure>
    <time_frame>4-8 months after starting methotrexate</time_frame>
    <description>Mean quality of life scores in the Quality of My Life scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MISS questionnaire</measure>
    <time_frame>4-8 months after starting methotrexate</time_frame>
    <description>Mean scores in the MISS questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <arm_group>
    <arm_group_label>Ondansetron premedication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate and folic/folinic acid as prescribed by physician. Ondansetron: 2 mg if &lt;15Kg, 4 mg if 15-30Kg, 8 mg if &gt;30Kg to be taken by mouth one hour before each weekly methotrexate dose, followed by two additional doses every 6-8 hours if awake. To be started from the very first dose of methotrexate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ondansetron as needed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methotrexate and folic/folinic acid as prescribed by physician. ONLY children who report nausea/vomiting during regular care will be prescribed ondansetron at the same dose as in experimental group (2 mg if &lt;15Kg, 4 mg if 15-30Kg, 8 mg if &gt;30Kg to be taken by mouth one hour before each weekly methotrexate dose, followed by two additional doses every 6-8 hours if awake), as per the attending rheumatologist's discretion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Children in both the intervention and control group will receive Methotrexate dose as prescribed by the rheumatologist</description>
    <arm_group_label>Ondansetron as needed</arm_group_label>
    <arm_group_label>Ondansetron premedication</arm_group_label>
    <other_name>Trexall</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Children in the intervention group will be prescribed premedication with oral ondansetron.
Children in the control group will be prescribed ondansetron ONLY if the child reports nausea/vomiting during regular treatment care with Methotrexate</description>
    <arm_group_label>Ondansetron as needed</arm_group_label>
    <arm_group_label>Ondansetron premedication</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages 4-16 years

          2. Diagnosis of JIA as per ILAR criteria, irrespective of JIA category

          3. Followed at a CAPRI centre in Canada

          4. Starting methotrexate to control JIA manifestations (arthritis, uveitis, psoriasis)

          5. Informed written consent to participate

        Exclusion Criteria:

          1. Previous use of methotrexate

          2. Known allergy to ondansetron

          3. Known congenital Long-QT syndrome

          4. Family unable to complete questionnaires in English or French
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaime Guzman, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaime Guzman, MD, FRCPC</last_name>
    <phone>604-875-2437</phone>
    <email>jguzman@cw.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Felice Mizan</last_name>
    <phone>6048752000</phone>
    <phone_ext>4839</phone_ext>
    <email>felice.mizan@cw.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Calgary / Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heinrike Schmeling, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dax Rumsey, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BC Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jaime Guzman, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Manitoba/Children's hospital research institute</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kerstin Gerhold, MD, MSc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial University/Janeway Childrens Health and Rehabilitation Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Dancey, MD, FRCPC</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Huber, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>McMaster University/McMaster Children's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michelle Batthish, MD, FRCPC</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberta Berard, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ciaran Duffy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brian Feldman, MD, MSc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaëlle Chédeville, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Barsalou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra Bruns, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alan Rosenberg, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/011719s117lbl.pdf</url>
    <description>Food and Drug Administration prescribing information for methotrexate.</description>
  </link>
  <link>
    <url>http://acrabstracts.org/abstract/perceptions-of-methotrexate-intolerance-in-school-aged-children-with-juvenile-idiopathic-arthritis/.</url>
    <description>Hopper C, Khan S, Mancini J, Rennick J. Perceptions of Methotrexate Intolerance in School-aged Children With Juvenile Idiopathic Arthritis [abstract].Arthritis Rheumatol. 2017; 69 (suppl 4).</description>
  </link>
  <link>
    <url>http://www.ped-rheum.com/content/12/S1/P199</url>
    <description>Da Silva C, Farias A, Sinicato N, Veloso R, Marini R, Appenseller S. Reasons for stopping methotrexate treatment in patients with juvenile idiopathic arthritisPediatric Rheumatology 2014, 12(Suppl 1):P199 (abstract)</description>
  </link>
  <link>
    <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020103s030,020605s014,020781s014lbl.pdf</url>
    <description>Ondansetron prescribing information, US Food and Drug Administration</description>
  </link>
  <link>
    <url>https://www.formulary.health.gov.on.ca/formulary/</url>
    <description>Ontario Drug Benefit Formulary</description>
  </link>
  <link>
    <url>https://pharmacareformularysearch.gov.bc.ca/faces/Search.xhtml</url>
    <description>BC Pharmacare Drug Formulary</description>
  </link>
  <link>
    <url>http://phrma-docs.phrma.org/sites/default/files/pdf/biopharmaceutical-industry-sponsored-clinical-trials-impact-on-state-economies.pdf</url>
    <description>Battelle Technology Partnership Practice: Biopharmaceutical Industry-Sponsored Clinical Trials: Impact on State Economies. March 2015.</description>
  </link>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/abs/10.1111/anzs.12151</url>
    <description>Analysis of Categorical Data with R By C. R. Bilder and T. M. Loughin. Boca Raton, Florida: Chapman and Hall/CRC. 2014. 547 pages.</description>
  </link>
  <reference>
    <citation>Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P; International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004 Feb;31(2):390-2.</citation>
    <PMID>14760812</PMID>
  </reference>
  <reference>
    <citation>Shiff NJ, Lix LM, Joseph L, Duffy C, Tucker LB, Svenson LW, Belisle P, Bernatsky S. The prevalence of systemic autoimmune rheumatic diseases in Canadian pediatric populations: administrative database estimates. Rheumatol Int. 2015 Mar;35(3):569-73. doi: 10.1007/s00296-014-3136-6. Epub 2014 Sep 26.</citation>
    <PMID>25257764</PMID>
  </reference>
  <reference>
    <citation>ANSELL BM, BYWATERS EG. RHEUMATOID ARTHRITIS (STILL'S DISEASE). Pediatr Clin North Am. 1963 Nov;10:921-39.</citation>
    <PMID>14145024</PMID>
  </reference>
  <reference>
    <citation>Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, Fink CW, Newman AJ, Cassidy JT, Zemel LS. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med. 1992 Apr 16;326(16):1043-9.</citation>
    <PMID>1549149</PMID>
  </reference>
  <reference>
    <citation>Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011 Apr;63(4):465-82. doi: 10.1002/acr.20460. Review.</citation>
    <PMID>21452260</PMID>
  </reference>
  <reference>
    <citation>Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, Scuccimarri R, Berard R, Tse SM, Morishita K, Stringer E, Johnson N, Levy DM, Duffy KW, Cabral DA, Rosenberg AM, Larché M, Dancey P, Petty RE, Laxer RM, Silverman E, Miettunen P, Chetaille AL, Haddad E, Houghton K, Spiegel L, Turvey SE, Schmeling H, Lang B, Ellsworth J, Ramsey S, Bruns A, Campillo S, Benseler S, Chédeville G, Schneider R, Yeung R, Duffy CM; ReACCh-Out investigators. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis. 2015 Oct;74(10):1854-60. doi: 10.1136/annrheumdis-2014-205372. Epub 2014 May 19.</citation>
    <PMID>24842571</PMID>
  </reference>
  <reference>
    <citation>Falvey S, Shipman L, Ilowite N, Beukelman T. Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2017 Jun 19;15(1):52. doi: 10.1186/s12969-017-0180-2. Review.</citation>
    <PMID>28629458</PMID>
  </reference>
  <reference>
    <citation>Bulatović M, Heijstek MW, Verkaaik M, van Dijkhuizen EH, Armbrust W, Hoppenreijs EP, Kamphuis S, Kuis W, Egberts TC, Sinnema G, Rademaker CM, Wulffraat NM. High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis Rheum. 2011 Jul;63(7):2007-13. doi: 10.1002/art.30367.</citation>
    <PMID>21437879</PMID>
  </reference>
  <reference>
    <citation>Dupont-Lucas C, Grandjean-Blanchet C, Leduc B, Tripcovici M, Larocque C, Gervais F, Jantchou P, Amre D, Deslandres C. Prevalence and Risk Factors for Symptoms of Methotrexate Intolerance in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Feb;23(2):298-303. doi: 10.1097/MIB.0000000000001014.</citation>
    <PMID>28107279</PMID>
  </reference>
  <reference>
    <citation>Mulligan K, Wedderburn LR, Newman S. The experience of taking methotrexate for juvenile idiopathic arthritis: results of a cross-sectional survey with children and young people. Pediatr Rheumatol Online J. 2015 Dec 12;13:58. doi: 10.1186/s12969-015-0052-6.</citation>
    <PMID>26653415</PMID>
  </reference>
  <reference>
    <citation>van Dijkhuizen EH, Bulatović Ćalasan M, Pluijm SM, de Rotte MC, Vastert SJ, Kamphuis S, de Jonge R, Wulffraat NM. Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study. Pediatr Rheumatol Online J. 2015 Feb 18;13:5. doi: 10.1186/s12969-015-0002-3. eCollection 2015.</citation>
    <PMID>25745368</PMID>
  </reference>
  <reference>
    <citation>Bechard MA, Lemieux JR, Roth J, Watanabe Duffy K, Duffy CM, Aglipay MO, Jurencak R. Procedural pain and patient-reported side effects with weekly injections of subcutaneous methotrexate in children with rheumatic disorders. Pediatr Rheumatol Online J. 2014 Dec 19;12:54. doi: 10.1186/1546-0096-12-54. eCollection 2014.</citation>
    <PMID>25584042</PMID>
  </reference>
  <reference>
    <citation>Klotsche J, Minden K, Niewerth M, Horneff G. Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA. Ann Rheum Dis. 2018 Jul;77(7):996-1002. doi: 10.1136/annrheumdis-2017-211968. Epub 2018 Feb 16.</citation>
    <PMID>29453217</PMID>
  </reference>
  <reference>
    <citation>Scheuern A, Tyrrell PN, Haas JP, Hügle B. Countermeasures against methotrexate intolerance in juvenile idiopathic arthritis instituted by parents show no effect. Rheumatology (Oxford). 2017 Jun 1;56(6):901-906. doi: 10.1093/rheumatology/kew507.</citation>
    <PMID>28122960</PMID>
  </reference>
  <reference>
    <citation>Schoemaker CG, van Dijkhuizen EHP, Vastert SJ. Contradictory and weak evidence on the effectiveness of anti-emetics for MTX-intolerance in JIA-patients. Pediatr Rheumatol Online J. 2018 Feb 15;16(1):13. doi: 10.1186/s12969-018-0229-x.</citation>
    <PMID>29448947</PMID>
  </reference>
  <reference>
    <citation>Phillips RS, Friend AJ, Gibson F, Houghton E, Gopaul S, Craig JV, Pizer B. Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood. Cochrane Database Syst Rev. 2016 Feb 2;2:CD007786. doi: 10.1002/14651858.CD007786.pub3. Review.</citation>
    <PMID>26836199</PMID>
  </reference>
  <reference>
    <citation>Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med. 1990 Mar 22;322(12):810-6.</citation>
    <PMID>1689807</PMID>
  </reference>
  <reference>
    <citation>De Mulder PH, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL, Beranek P, Verweij J. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med. 1990 Dec 1;113(11):834-40.</citation>
    <PMID>2146911</PMID>
  </reference>
  <reference>
    <citation>Dick GS, Meller ST, Pinkerton CR. Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. Arch Dis Child. 1995 Sep;73(3):243-5.</citation>
    <PMID>7492164</PMID>
  </reference>
  <reference>
    <citation>Kempinska A, Benchimol EI, Mack A, Barkey J, Boland M, Mack DR. Short-course ondansetron for the prevention of methotrexate-induced nausea in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2011 Oct;53(4):389-93. doi: 10.1097/MPG.0b013e31822855e7.</citation>
    <PMID>21681112</PMID>
  </reference>
  <reference>
    <citation>Blanco R, González-Gay MA, García-Porrúa C, Ibañez D, García-Pais MJ, Sánchez-Andrade A, Vázquez-Caruncho M. Ondansetron prevents refractory and severe methotrexate-induced nausea in rheumatoid arthritis. Br J Rheumatol. 1998 May;37(5):590-2.</citation>
    <PMID>9651100</PMID>
  </reference>
  <reference>
    <citation>Cubeddu LX, Pendergrass K, Ryan T, York M, Burton G, Meshad M, Galvin D, Ciociola AA. Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group. Am J Clin Oncol. 1994 Apr;17(2):137-46.</citation>
    <PMID>8141105</PMID>
  </reference>
  <reference>
    <citation>Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK, Lahdenne P, Horneff G, Calvo I, Szer IS, Simpson K, Stewart JA, Strand V; Leflunomide in Juvenile Rheumatoid Arthritis (JRA) Investigator Group. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005 Apr 21;352(16):1655-66.</citation>
    <PMID>15843668</PMID>
  </reference>
  <reference>
    <citation>Ford I, Norrie J. Pragmatic Trials. N Engl J Med. 2016 Aug 4;375(5):454-63. doi: 10.1056/NEJMra1510059.</citation>
    <PMID>27518663</PMID>
  </reference>
  <reference>
    <citation>Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30.</citation>
    <PMID>18929686</PMID>
  </reference>
  <reference>
    <citation>Bhatt DL, Mehta C. Adaptive Designs for Clinical Trials. N Engl J Med. 2016 Jul 7;375(1):65-74. doi: 10.1056/NEJMra1510061. Review.</citation>
    <PMID>27406349</PMID>
  </reference>
  <reference>
    <citation>Efird J. Blocked randomization with randomly selected block sizes. Int J Environ Res Public Health. 2011 Jan;8(1):15-20. doi: 10.3390/ijerph8010015. Epub 2010 Dec 23.</citation>
    <PMID>21318011</PMID>
  </reference>
  <reference>
    <citation>Chausset A, Fargeix T, Pereira B, Echaubard S, Duquesne A, Desjonquères M, Freychet C, Belot A, Merlin E. MISS questionnaire in French version: a good tool for children and parents to assess methotrexate intolerance. Clin Rheumatol. 2017 Jun;36(6):1281-1288. doi: 10.1007/s10067-017-3638-1. Epub 2017 May 5.</citation>
    <PMID>28477218</PMID>
  </reference>
  <reference>
    <citation>Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N; Childhood Arthritis Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Paediatric Rheumatology International Trials Organisation. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011 Jul;63(7):929-36. doi: 10.1002/acr.20497.</citation>
    <PMID>21717596</PMID>
  </reference>
  <reference>
    <citation>Feldman BM, Grundland B, McCullough L, Wright V. Distinction of quality of life, health related quality of life, and health status in children referred for rheumatologic care. J Rheumatol. 2000 Jan;27(1):226-33.</citation>
    <PMID>10648043</PMID>
  </reference>
  <reference>
    <citation>Otto C, Barthel D, Klasen F, Nolte S, Rose M, Meyrose AK, Klein M, Thyen U, Ravens-Sieberer U. Predictors of self-reported health-related quality of life according to the EQ-5D-Y in chronically ill children and adolescents with asthma, diabetes, and juvenile arthritis: longitudinal results. Qual Life Res. 2018 Apr;27(4):879-890. doi: 10.1007/s11136-017-1753-8. Epub 2017 Nov 30.</citation>
    <PMID>29189988</PMID>
  </reference>
  <reference>
    <citation>Schoenfeld DA. A simple algorithm for designing group sequential clinical trials. Biometrics. 2001 Sep;57(3):972-4.</citation>
    <PMID>11550952</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Jaime Guzman</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Arthritis</keyword>
  <keyword>Arthritis, Juvenile</keyword>
  <keyword>Joint Diseases</keyword>
  <keyword>Rheumatic diseases</keyword>
  <keyword>Pragmatic Trials</keyword>
  <keyword>Ondansetron</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Nausea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>If the ethics boards at all participating centres approve individual participant data sharing we will upload to clinicaltrials.gob a data sharing plan at that time.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

